Shai Shimony
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Year:
2026
Year:
2026
The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving asparaginase-based induction. We conducted a multicenter retrospective cohort study of patients (aged ≥18 years) with newly diagnosed ALL receiving asparaginase-based induction. The derivation and external validation cohorts included 306 and 94 patients, respectively. Primary outcome was VTE at any site. A cause-specific Cox proportional hazards model stratified by thromboprophylaxis and center was performed to identify VTE risk factors in the derivation cohort. A risk prediction model for VTE at 30 days was derived using variables with P value < .05 in the multivariable model and was tested in the validation cohort. VTE risk factors on multivariable analysis in the derivation cohort included D-dimer ≥1 μg fibrinogen equivalent unit per mL (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.07-6.5) and hemoglobin (HR for each 1 g/dL increment, 1.19; 95% CI, 1.06-1.34) at ALL diagnosis. A VTE risk score based on these variables distinguished between a 4% (95% CI, 0.72-12) and 20% (95% CI, 14-27) 30-day cumulative incidence of VTE in the derivation cohort, with similar findings in the validation cohort (area under the curve, 0.56). The negative predictive value for VTE at 30 days was 96% and 93% in the derivation and validation cohorts, respectively, and the positive predictive value was 20% in both. We derived and validated a model using D-dimer and hemoglobin, which stratifies VTE risk in patients with ALL receiving asparaginase-based induction.
Year:
2026
Survival outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have improved with modern frontline therapies and minimal residual disease (MRD)‐guided strategies. As a result, allogeneic hematopoietic cell transplantation (HCT) is increasingly deferred in first remission (CR1) and used in the relapsed setting. However, data on HCT outcomes in second remission (CR2) remain limited in AYAs. We conducted a dual‐center retrospective study of AYA patients aged 15–40 years who underwent HCT in CR2 between 2010 and 2022. Among 164 patients, the median age was 25 years; 66% were male and 80% had B‐ALL. Frontline therapies included pediatric‐inspired (54%) and hyperCVAD‐based (33%) regimens. Most received myeloablative conditioning (74%), and 67% were MRD‐negative at HCT. At a median follow‐up of 36 months, 3‐year overall survival (OS) and progression‐free survival (PFS) were 53% and 46%. The 3‐year cumulative incidences of relapse and non‐relapse mortality were 36% and 18%, respectively. The 6‐month incidence of grade 2–4 acute graft‐versus‐host disease (GVHD) was 36%, and grade 3–4 was 14%. Chronic GVHD occurred in 27% at 3 years, with 37% moderate and 25% severe. On multivariable analysis, a HCT‐specific comorbidity index > 3 was independently associated with inferior OS, PFS, and higher non‐relapse mortality. MRD positivity predicted worse PFS and higher relapse risk but not OS. These findings support HCT in CR2 as a curative option for AYA patients with ALL. Outcomes are influenced by MRD status and comorbidities, underscoring the need for risk‐adapted transplant strategies.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Previous studies have demonstrated that social determinants of health (SDOH) are associated with overall survival (OS) in patients with acute myeloid leukemia (AML). Their interaction with the European LeukemiaNet (ELN) 2022 genetic risk criteria remains unclear. We evaluated the impact of SDOH, measured by the national Area Deprivation Index (nADI) and categorized as low (<=50; more advantaged) vs. high (>50; less advantaged), in 365 patients with newly diagnosed AML treated with intensive chemotherapy. Among ELN favorable (n=115) and adverse (n=166) risk groups, overall survival was similar for high and low nADI groups. Conversely, in intermediate risk patients (n=84), overall survival was higher for more advantaged patients (median 33 vs. 17 months, p=0.04), which persisted in multivariable analysis adjusted for age, race, sex, and hematopoietic cell transplantation as a time-varying covariate (HR 3.09, 95% confidence interval [CI] 1.3-7.34, p=0.01). In this intermediate risk group, response and transplantation rates did not differ by nADI group. Among patients consolidated with transplantation (59/84, 70%), survival was prolonged for more advantaged patients, although not significantly (2-year OS: 69% and 58%; p=0.069), which appeared to be mediated by a higher relapse rate (3-year cumulative incidence of 35% and 69%, p=0.06) rather than non-relapse mortality (20% and 19%, p=0.8). In conclusion, for patients with AML treated with intensive chemotherapy, more advantaged SDOH was associated with improved overall survival solely in the ELN intermediate risk group. This improvement appeared to be mediated by lower post-transplant relapse.
Year:
2026
CPX-351 was approved for treatment of acute myeloid leukemia (AML) using now-outdated definitions of AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML. We evaluated whether the overall survival (OS) benefit of CPX-351 over 7+3 is confined to molecularly-defined AML subgroups by performing DNA sequencing in 184 patients enrolled in the pivotal phase 3 randomized trial. Patients were categorized hierarchically based on gene mutations: (1) TP53-AML, (2) DDX41-AML, (3) myelodysplasia-related AML (AML-MR) defined by WHO 5th edition, or (4) other-AML. TP53-AML was subclassified as single (TP53single) or multihit (TP53multi) based on the number of alleles altered via mutation, deletion, or copy-neutral loss of heterozygosity. Two-year OS differed significantly across molecular subgroups: TP53-AML (7%), AML-MR (19%), other-AML (37%), and DDX41-AML (70%) p<0.001. CPX-351 improved survival in AML-MR patients compared to 7+3 (median: 9.7 vs 6.8 months, p=0.037), with no benefit in TP53-AML or other-AML. For patients undergoing transplantation, CPX-351 improved 2-year survival (76% vs 27%; p<0.01), an effect primarily observed in AML-MR. Multivariable analysis confirmed the independent association with survival of both CPX-351 and HCT in AML-MR. TP53multi demonstrated significantly worse survival than TP53single (median 3.8 vs 7.0 months; p=0.004). The OS benefit of CPX-351 observed in the trial was driven by AML-MR with no benefit of CPX-351 in TP53-AML, where the primary prognostic factor was allelic state. Clinical Trial Information: NCT01696084
Year:
2026
Background The GALLIUM trial showed improved progression‐free survival (PFS) with obinutuzumab (O)‐based chemoimmunotherapy in first‐line treatment of follicular lymphoma (FL), although with increased toxicity compared to rituximab (R). Our previous real‐world study found similar toxicity between these protocols during induction. Aim To compare real‐world toxicity and outcomes of R versus O maintenance therapy in FL patients following first‐line chemoimmunotherapy. Methods A multicenter retrospective study included FL patients treated with first‐line R‐ or O‐based chemoimmunotherapy. The primary outcome was any infection up to 6 months post‐maintenance. Secondary outcomes included other toxicities, PFS, and overall survival (OS). Results We analyzed 134 patients (R: 71, O: 63). Baseline characteristics were similar except for higher diabetes and hypertension rates in the R group. The median number of maintenance cycles was comparable. Infections occurred in 56% of patients, with no significant difference (50.7% R vs. 61.9% O, p = 0.21). Grade 3 infections, febrile neutropenia, and treatment discontinuation rates were comparable between groups. Pneumonia and viral infections were less frequent with R versus O (13.8% vs. 28.1%, p = 0.019 and 19% vs. 39%, p = 0.004, respectively), while infusion reactions were higher (8.4% vs. 0%, p = 0.028). After 5.5 years, PFS favored O (19.7% vs. 4.8%, p = 0.028), with similar OS. Conclusions In real‐world settings, rituximab‐ and obinutuzumab‐based chemoimmunotherapy with maintenance for FL exhibited a similar toxicity profile, with differences in specific infections. Obinutuzumab had superior PFS and similar OS compared with rituximab therapy, supporting obinutuzumab usage in first‐line chemoimmunotherapy, especially in selected young and fit patients.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Collaborators (21)
Vikas Gupta
-
Marlise Luskin
Dana-Farber Cancer Institute
Richard Stone
Dana-Farber Cancer Institute
Benjamin Rolles
Stanford University
Talha Badar
Leukemia Attending
Mayo Clinic Florida
Tara Lin
University of Kansas Medical Center
Evan Chen
Dana-Farber Cancer Institute
Matthew Booker
Dana-Farber Cancer Institute
Jeremy Ryan
Staff Scientist
Dana-Farber Cancer Institute
Lachelle Dawn Weeks
Dana-Farber Cancer Institute
Oren Pasvolsky
The University of Texas MD Anderson Cancer Center
Nicholas J. Short
-
Daniel DeAngelo
Chief of the Division of Leukemia
Dana-Farber Cancer Institute
Andrew Lane
Dana-Farber Cancer Institute
Angela Feraco
Dana-Farber Cancer Institute
Elias J. Jabbour
Professor
The University of Texas MD Anderson Cancer Center
Gabriel Griffin
Dana-Farber Cancer Institute
Jorge Cortes
Chair of Hematology
Augusta University
Giada Bianchi
Harvard University
Zuzana Tothova
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Anju Nohria
Site-Director, Cardio-Oncology, Manhattan
NYU Langone Health
Make your next move.
Prepare your application
Review drafts before you send them.